Updated Guidelines for Managing Clostridioides difficile Infection in Adults

Fidaxomicin and bezlotoxumab are conditionally recommended.

Sponsoring Organization: Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology (SHEA)

Target Audience: Infectious disease clinicians, gastroenterologists, hospitalists, pharmacists, and any other healthcare personnel caring for adult patients with C. difficile infection

Background and Objective

The Clostridioides (formerly Clostridium) difficile infection (CDI) guidelines from IDSA/SHEA were last revised in 2017 (NEJM JW Infect Dis May 2018 and Clin Infect Dis 2018; 66:e1). This update specifically concerns use of fidaxomicin and bezlotoxumab.

Key Points

Fidaxomicin is preferred over oral vancomycin for first cases of CDI.
Fidaxomicin as either continuous or pulse therapy is recommended over oral vancomycin for…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)